Production of cell culture media in South Korea
In South Korea, Satorius will invest around 270 million euros ($ 300 million) by the end of 2024.
At the Songdo Biopharmaceutical Center in Incheon, the company will start production of cell culture media and assemble sterile systems for efficient and flexible manufacturing of biopharmaceuticals, as well as other operations. The investment will serve both South Korean and wider Asian markets.
The company’s site will cover some 25,000 square meters (270,000 square feet) and include an application center with laboratories as well as several buildings for manufacturing and logistics.
Sartorius’ existing activities in South Korea for service as well as marketing and sales will be transferred to the new site, which provides space for further extensions. Construction work on the site is expected to begin in the coming year and production operations are expected to start by the end of 2024.
Sartorius currently employs 180 people in South Korea, but will employ 750 more as part of the investment.
Sartorius Chairman and CEO Joachim Kreuzburg said: “The development of the biopharmaceutical industry in Asia and, in particular, South Korea, has entered a new phase characterized by a high rate of innovation and investment on the part of our customers.
“With our significant investments in Songdo, we will increase our capacity, bring production operations closer to our customers in the region, and dramatically increase our speed of delivery. “
French investment on three sites
In France, Sartorius will increase the capacity of its Aubagne, Cergy and Lourdes facilities in order to meet strong demand from the biopharmaceutical industry.
An investment of 100 million euros ($ 113 million) between 2021 and 2025 will be used to modernize the three sites, as well as to create 400 new permanent jobs in French operations.
The largest part of the investment will be devoted to the construction of new clean rooms and R&D laboratories at the French headquarters of Sartorius in Aubagne, near Marseille.
The investment will almost double the size of the company’s clean rooms in the country: 4,000 square meters will be added to the existing 5,000 square meters.
New R&D laboratories covering nearly 2,000 square meters will also be added.
The company’s logistics platforms will be modernized with the addition of more than 10,000 square meters of warehouses and storage depots. Equipment will be digitized and automated to increase capacity and create a competitive advantage, the company adds.
Satorius currently employs around 1,100 people on permanent contracts in France at four different sites in Aubagne, Cergy, Dourdan and Lourdes. Up to 400 new permanent jobs will be created at the sites: notably in operations (such as production managers, machine operators, continuous improvement managers) and product development (including engineers, data analysts and marketing staff).
“We see our biopharmaceutical customers entering a new phase characterized by a high pace of innovation, substantial investments in their operations and increasing demands on us as suppliers. We support their efforts, significantly increasing capacity and increasing the speed of delivery. “Commented Luc Burgard, Managing Director of Sartorius Stedim FMT and Head of Operations for the Bioprocess Solutions Division at Sartorius. “Investments in our French facilities will strengthen our industrial capacities in this country and ensure the sustainability of our operations here. “